Multiple Myeloma Research Consortium (MMRC) Welcomes the Barbara Ann Karmanos Cancer Institute as Member Institution

Early-Stage Drug Development Consortium Expands Research Network

NORWALK, Conn.--(BUSINESS WIRE)-- The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. Following a rigorous evaluation, this NCI-designated comprehensive cancer center joins the existing MMRC member institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

“We are proud to join such a highly respected model for accelerating the development of new treatment options for multiple myeloma patients,” said Jeffrey Zonder, M.D., associate professor of Medicine and Oncology, Karmanos Cancer Institute and Wayne State University School of Medicine. “We are very much looking forward to collaborating with the MMRC, its elite member institutions, and its partners in the biotech and pharmaceutical industries to bring patients the next generation of multiple myeloma treatments.”

As an MMRC member institution, Karmanos will participate in all clinical research activities of the Consortium, including the conduction of Phase I and II clinical trials of promising myeloma treatments. In this role, Karmanos will also contribute multiple myeloma patient tissue samples to the MMRC Tissue Bank, a cutting-edge resource that bridges laboratory and clinical research.

"We are pleased to welcome Karmanos Cancer Institute to the MMRC's esteemed clinical network," said Beverly Harrison, VP, Clinical Development. "Like all MMRC Member Institutions, Karmanos was selected to join this exclusive network based on its outstanding reputation for clinical excellence, its demonstrated commitment to rigorous research, and its true spirit of collaboration and team-science. We have no doubt that Karmanos will prove to be an invaluable asset in our efforts to rapidly shepherd the next generation of treatments through the MMRC."

About the MMRC:

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University. The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is an affiliate organization of the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas–genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit:

About Barbara Ann Karmanos Cancer Institute:

Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation’s best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Karmanos is southeastern Michigan’s most preferred hospital for cancer care according to annual surveys conducted by the National Research Corporation. Gerold Bepler, M.D., Ph.D., is the Institute’s president and chief executive officer. For more information call 1-800-KARMANOS or go to

For more information on the Karmanos Cancer Institute’s multiple myeloma clinical trials, contact Silvana Pregja at 313-576-8673 or email [email protected].


For Karmanos Cancer Institute
Silvana Pregja, 313-576-8673
[email protected]
For the MMRC
Beverly Harrison, 203-652-0213
[email protected]

KEYWORDS:   United States  North America  Connecticut  Michigan

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Clinical Trials  Genetics  Pharmaceutical  Philanthropy  Research  Other Science  Science  Foundation  Fund Raising  General Health